Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations.
BACKGROUND
Papillary serous carcinoma of the peritoneum (PSCP) diffusely involves peritoneal surfaces, while it spares or only superficially involves the ovaries. PSCP is histologically indistinguishable from serous epithelial ovarian carcinoma, and it may develop years after oophorectomy. The molecular pathogenesis of PSCP remains unresolved, although preliminary data suggest a multifocal origin in some cases. Patients with germline BRCA1 mutations may develop PSCP in addition to breast and ovarian carcinomas. The purpose of this study was to utilize the androgen receptor (AR) gene locus to test the hypothesis that some cases of PSCP have a multifocal origin and to determine if patients with germline BRCA1 mutations develop multifocal PSCP.


METHODS
Specimens of normal and tumor tissues from 22 women with PSCP were obtained, and DNA was extracted. The AR gene locus was evaluated for patterns of loss of heterozygosity (LOH) and X-chromosome inactivation. The methylation-sensitive Hpa II restriction enzyme was used to differentiate the active and inactive X chromosomes. Germline BRCA1 mutation status of the patients was determined previously.


RESULTS
Genetic analysis of tumor specimens indicated that five (23%) of 22 case subjects had patterns of selective LOH at the AR locus, consistent with multifocal, polyclonal disease origin. Two patients with selective LOH also had alternating X-chromosome inactivation patterns. Patients with germline BRCA1 mutations were more likely to have evidence of multifocal disease (two-sided Fisher's exact test, P = .01).


CONCLUSIONS
Our results show that PSCP has a multifocal origin in at least some cases. Furthermore, patients with germline BRCA1 mutations are more likely to develop multifocal PSCP than are patients without BRCA1 mutations.
Schorge
J O
JO
Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. JOSCHORGE@BICS.BWH.HARVARD.EDU
Muto
M G
MG
Welch
W R
WR
Bandera
C A
CA
Rubin
S C
SC
Bell
D A
DA
Berkowitz
R S
RS
Mok
S C
SC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D014408:Biomarkers, Tumor / Q000235:genetics*; D002999:Clone Cells / Q000648:ultrastructure; D018283:Cystadenocarcinoma, Papillary / Q000235:genetics / Q000473:pathology*; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000235:genetics*; D004198:Disease Susceptibility; D004303:Dosage Compensation, Genetic; D005260:Female; D019398:Genes, BRCA1; D016158:Genes, p53; D005819:Genetic Markers; D006801:Humans; D019656:Loss of Heterozygosity; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000648:ultrastructure; D009386:Neoplastic Syndromes, Hereditary / Q000235:genetics* / Q000473:pathology; D010052:Ovariectomy; D010053:Ovary / Q000196:embryology; D010534:Peritoneal Neoplasms / Q000235:genetics / Q000473:pathology*; D010537:Peritoneum / Q000196:embryology; D011944:Receptors, Androgen / Q000235:genetics*; D012189:Retrospective Studies; D018911:Trinucleotide Repeats; D014960:X Chromosome / Q000235:genetics
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D005819:Genetic Markers; D011944:Receptors, Androgen